Andrew Staron, MD is an Assistant Professor of Medicine in Hematology & Medical Oncology at the Chobanian and Avedisian School of Medicine. He was appointed to this position after completing his residency (2015–2018) and fellowship (2019–2022) at Boston Medical Center. In his third year of fellowship, Dr. Staron was selected for the role of chief fellow. Additionally, he completed a year-long clinical and research fellowship in amyloidosis (2018–2019) at the Boston University Amyloidosis Center, under the mentorship of the director, Dr. Sanchorawala.
As a practicing hematologist at Boston Medical Center, Dr. Staron has a deep commitment to serving patients and families who are affected by various hematologic diseases and who come from diverse backgrounds, drawing upon his own upbringing in an immigrant family. His main research interest is in AL amyloidosis—a rare plasma cell disorder that leads to the accumulation of abnormal immunoglobulin light chain proteins in organs. He has been the lead author on several publications in peer-reviewed journals and given presentations related to AL amyloidosis at national and international meetings. Dr. Staron helps to oversee the clinical database at the Boston University Amyloidosis Center and is directly involved in research projects utilizing this resource. He has conducted natural history studies that described important trends in disease outcomes and explored the role of minimal residual disease assessment in AL amyloidosis. Dr. Staron is also a member of the International Society of Amyloidosis and a peer-reviewer for several journals.
Diversity, Equity, Inclusion and Accessibility
"In 2015, I started my internal medicine residency at Boston Medical Center—the largest safety net hospital in New England—with a strong commitment to making a difference in the lives of people from underprivileged and marginalized communities. The work was eye-opening and humbling, shaping me into a more thoughtful and compassionate physician. I learned how members of minority groups often face discrimination in various aspects of life, including housing, education, employment and healthcare. During my early training years, I realized the importance of supporting diversity, equity, inclusion and accessibility in my future career. These attributes of my experience led me to stay at Boston Medical Center for my fellowship training in hematology/oncology, where I learned how cancer is more than a disease. Each day, I saw the ways in which cancer interplays with sociocultural, language, economic and lifestyle obstacles.
Now as a practicing hematologist at Boston Medical Center, I strive to bridge access to the most cutting-edge diagnostic modalities and treatments for members of all underrepresented groups—e.g., ethnic, racial, religious, and sexual minorities, among others.
I also support diversity and equity through my research efforts, by studying and tackling the historic racial and ethnic inequalities that are pervasive within the field of cancer. In particular, I am struck by the low representation of minorities in clinical trials, despite having a disproportionately higher risk of certain diseases—e.g., plasma cell disorders like multiple myeloma are more prevalent among Black Americans. I conducted a study investigating racial and ethnic disparities in a rare plasma cell disorder called AL amyloidosis, and found that differences in health outcomes among minorities were largely explained by lower educational level and later recognition of disease, rather than race and ethnicity itself. I concluded that, in order to mitigate disparities in this disease, earlier disease detection and concerted efforts to reduce economic and/or language barriers are key."
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 15 results.
Gustine JN, Staron A, Mendelson L, Joshi T, Gopal DM, Siddiqi OK, Ruberg FL, Sanchorawala V. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Adv. 2023 Oct 24; 7(20):6080-6091.View Related Profiles. PMID: 37581513
Freydman J, Staron A, Hughes D, Sloan JM. Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome. J Oncol Pharm Pract. 2023 Sep; 29(6):1489-1493.View Related Profiles. PMID: 37157792
Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199.View Related Profiles. PMID: 35731907
Staron A, Verma K, Sanchorawala V. Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis. Br J Haematol. 2022 Sep; 198(5):861-865.View Related Profiles. PMID: 35499208
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
2022 International Society of Amyloidosis Presidential Award
2020-2021 American Society of Hematology Abstract Achievement Award
2020 Amyloidosis Foundation Travel Grant
2014 Wellsford and Mildred Clark Medical Memorial:
2014 Dr. Frank and Florence Marino Scholarship Award